daratumumab + corticosteroid

Daratumumab + corticosteroid is a combination regimen used primarily in the treatment of multiple myeloma. Daratumumab is a human IgG1κ monoclonal antibody that targets CD38, a glycoprotein highly expressed on the surface of myeloma cells. By binding to CD38, daratumumab induces tumor cell death through several immune-mediated mechanisms including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). Corticosteroids such as dexamethasone or prednisone are commonly co-administered with daratumumab both as premedication to reduce infusion-related reactions and as part of multi-drug regimens for their anti-inflammatory and immunosuppressive effects. The combination enhances anti-myeloma efficacy and helps manage side effects associated with monoclonal antibody therapy[3][5][7][10].